



**OAS | CICAD**



**INTER-AMERICAN DRUG ABUSE  
CONTROL COMMISSION**

**CICAD**

Secretariat for Multidimensional Security

**LATIN AMERICAN TRAINING OF TRAINERS OF THE UNIVERSAL PREVENTION  
CURRICULUM FOR SUBSTANCE USE, SESSION IV  
November 18 - 22, 2019  
Cartagena, Colombia**

**OEA/Ser.L/XIV.2.66  
CICAD/doc.2503/19  
15 November 2019  
Original: English**

**SIX CANNABIS-RELATED RECOMMENDATIONS OF THE EXPERT COMMITTEE  
ON DRUG DEPENDENCE**

## **Six Cannabis-Related Recommendations of the Expert Committee on Drug Dependence**

- (1) To delete cannabis and cannabis resin from Schedule IV of the 1961 Convention;
- (2) To add dronabinol and its stereoisomers (delta-9-tetrahydrocannabinol) to Schedule I of the 1961 Convention; and to delete it from Schedule II of the 1971 Convention, subject to the Commission's adoption of the recommendation to add it to Schedule I of the 1961 Convention;
- (3) To add tetrahydrocannabinol (THC) (isomers of delta-9-tetrahydrocannabinol) to Schedule I of the 1961 Convention, subject to the Commission's adoption of the recommendation to add dronabinol and its stereoisomers to Schedule I of the 1961 Convention; and to delete THC from Schedule I of the 1971 Convention, subject to the adoption of the recommendation to add it to Schedule I of the 1961 Convention;
- (4) To delete extracts and tinctures of cannabis from Schedule I of the 1961 Convention;
- (5) To give effect to the recommendation of the Expert Committee on Drug Dependence at its fortieth meeting that preparations considered to be pure CBD should not be scheduled under the international drug control conventions, by adding a footnote to the entry for cannabis and cannabis resin in Schedule I of the 1961 Convention to read "Preparations containing predominantly cannabidiol and not more than 0.2 per cent of delta-9-tetrahydrocannabinol are not under international control";
- (6) To add to Schedule III of the 1961 Convention preparations containing delta-9-tetrahydrocannabinol (dronabinol), produced either by chemical synthesis or as preparations of cannabis that are compounded as pharmaceutical preparations with one or more other ingredients and in such a way that delta-9-tetrahydrocannabinol (dronabinol) cannot be recovered by readily available means or in a yield that would constitute a risk to public health.